EP-Solutions develops real-time cardiac mapping technology that enables simultaneous electrophysiology mapping of both epicardial and endocardial heart surfaces. Its second-generation AMYCARD system is CE Mark‑approved and builds on more than six years of clinical research involving over 750 patients. The company intends to use newly raised funds to further develop the AMYCARD system and support its clinical roll‑out in Europe and the USA. Management includes Dr. Werner Rainer (board member and CEO ad interim), Dr. Joaquin Azpilicueta (COO), and Drago A. Cerchiari (chairman). The company was founded in 2009 under the name Amycard and later incorporated in Switzerland as EP-Solutions following an acquisition and transfer of assets. EP-Solutions is based in Yverdon Les Bains, Switzerland.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2016